<DOC>
	<DOCNO>NCT01143337</DOCNO>
	<brief_summary>The purpose study determine Efficacy , Safety , Pharmacokinetics MP-435 administer 12 week subject rheumatoid arthritis ( RA ) stable dos Methotrexate .</brief_summary>
	<brief_title>Efficacy Safety Study MP-435 Combination With Methotrexate ( MTX ) Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Subjects diagnosis RA accord diagnostic criterion American College Rheumatology ( ACR ) ( revised 1987 ) least 6 month . Subjects inadequately response stable dose MTX . Patients Class IV functional activity Steinbrocker 's scale . Patients receive biological agent past . Patients rheumatic disease , disease joint symptom . Patients severe uncontrolled endocrine , psychiatric , cardiac , hematological , pulmonary , hepatic , kidney , gastrointestinal , thyroid disease .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>